A Phase 3 interventional study of Dexamethasone sodium phosphate and Placebo in Ataxia Telangiectasia, sponsored by Quince Therapeutics S.p.A.. Completed at 19 sites in 9 countries. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2026-04-30.
Sponsored by Quince Therapeutics S.p.A. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Ataxia Telangiectasia with a site in United States — 2 open to participants now, 4 under way, 1 of them phase 3. Ataxia Telangiectasia · United States.
Among the 16 studies in Ataxia Telangiectasia with a site in United States, this one has the largest enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2024, is one of 4 in phase 3, and was the 13th registered.
42 studies on the registry are indexed under Ataxia Telangiectasia; 7 are open to participants now.
Browse Ataxia Telangiectasia studies →2 of the 16 studies in Ataxia Telangiectasia with a site in United States are open now. Recruiting first, the newest first:
Timothy Yu · Sites in United States
Ages 0–17
Sanford Health · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 5 Ataxia Telangiectasia studies recruiting now, 3 set no upper age limit and 2 stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.
This study: 6 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 4
First in 2002; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 105 is above the median of 30 across 28 interventional studies indexed under Ataxia Telangiectasia.
Median enrollment 20 across the 13 interventional studies, 317 across the 3 observational. Of the 10 that completed or were terminated, 5 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 16 have an industry lead sponsor. The 10 most frequent:
Quince Therapeutics S.p.A. is the lead sponsor of 10 studies on the registry; none are open to participants now.
Quince Therapeutics S.p.A. has 4 studies filed under Ataxia Telangiectasia — fewer than ten, so there is no comparison to draw.
1 of the studies in Ataxia Telangiectasia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692596H. Lee Moffitt Cancer Center and Research InstituteThe Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies in Ataxia Telangiectasia with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an international, multi-center, randomized, prospective, double-blind, placebo-controlled, Phase 3 study, designed to assess the effect of EryDex (dexamethasone sodium phosphate [DSP] in autologous erythrocytes), administered by intravenous (IV) infusion once every 28 days, on neurological symptoms of patients with Ataxia Telangiectasia (A-T).
The EryDex System (EDS) is a combination product that is used to load dexamethasone sodium phosphate (DSP) into autologous erythrocytes (EryDex) which is infused into the patient.
In the placebo arm, the subjects will receive autologous erythrocytes prepared with the EDS process using a placebo solution.
Upon completion of all screening assessments for eligibility, subjects meeting all selection criteria at baseline will be randomized in a 1:1 fashion to EryDex or placebo. Approximately 86 subjects 6- to 9-years-old, approximately 43 per group, will be randomized. Approximately 20 subjects 10 years of age and above, 10 per treatment group, may also be enrolled.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
IV infusion of dexamethasone sodium phosphate (DSP) encapsulated in autologous erythrocytes using the EryDex System (EDS)
Drug: Dexamethasone sodium phosphate
IV infusion of placebo encapsulated in autologous erythrocytes using the EryDex System (EDS)
Other: Placebo
Dexamethasone sodium phosphate encapsulated in autologous erythrocytes and administered via IV infusion
Also known as: DSP
Placebo encapsulated in autologous erythrocytes and administered via IV infusion
Rescored Modified International Cooperative Ataxia Rating Scale (RmICARS)
Change of the RmICARS from baseline to Visit 9 compared to placebo (6 to 9 years old). RmICARS (International Cooperative Ataxia Rating Scale): Score (range 0-29); higher score indicates worse disease.
Time frame: Baseline to Visit 9 (approximately 6 months)
Clinical Global Impression of Severity (CGI-S)
CGI-S (Clinical Global Impression of Severity): 7-point scale; higher score indicates worse disease. 1 = Normal, not at all ill; 7 = Among the most extremely ill. Percentage of participants improving in CGI-S from baseline to Visit 9.
Time frame: Baseline to Visit 9 (approximately 6 months)
Clinical Global Impression of Change (CGI-C)
CGI-C (Clinical Global Impression of Change): 7-point scale; higher score indicates worsening of disease. 1 = Very much improved; 4 = No change; 7 = Very much worse. Percentage of participants improving in CGI-C at Visit 9
Time frame: Baseline to Visit 9 (approximately 6 months)
Participants were randomized (1:1) to eDSP or placebo group via an independent Interactive Web Response System and were stratified by age (6-9 years or ≥10 years), gender, and region (USA vs. other countries). 105 study participants were randomized and 105 received at least one study treatment.
| Milestone | Dexamethasone Sodium Phosphate | Placebo |
|---|---|---|
| Started | 51 | 54 |
| Completed | 49 | 52 |
| Not completed | 2 | 2 |
Change of the RmICARS from baseline to Visit 9 compared to placebo (6 to 9 years old). RmICARS (International Cooperative Ataxia Rating Scale): Score (range 0-29); higher score indicates worse disease.
| RmICARS score (0-29 points) | Dexamethasone Sodium Phosphate | Placebo |
|---|---|---|
| Rescored Modified International Cooperative Ataxia Rating Scale (RmICARS) | 0.94 ± 4.13 | 2.24 ± 3.42 |
CGI-S (Clinical Global Impression of Severity): 7-point scale; higher score indicates worse disease. 1 = Normal, not at all ill; 7 = Among the most extremely ill. Percentage of participants improving in CGI-S from baseline to Visit 9.
| Participants | Dexamethasone Sodium Phosphate | Placebo |
|---|---|---|
| Clinical Global Impression of Severity (CGI-S) | 8 | 7 |
CGI-C (Clinical Global Impression of Change): 7-point scale; higher score indicates worsening of disease. 1 = Very much improved; 4 = No change; 7 = Very much worse. Percentage of participants improving in CGI-C at Visit 9
| Participants | Dexamethasone Sodium Phosphate | Placebo |
|---|---|---|
| Clinical Global Impression of Change (CGI-C) | 13 | 6 |
Collected over Timeframe is from baseline (or first dose, as defined) to Visit 10 (approximately 6 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dexamethasone Sodium Phosphate | 0/51 (0%) | 2/51 (3.9%) | 47/51 (92.2%) |
| Placebo | 0/54 (0%) | 3/54 (5.6%) | 50/54 (92.6%) |
| Event | Dexamethasone Sodium Phosphate | Placebo |
|---|---|---|
| Lower respiratory tract infectionInfections and infestations | 1/51 | 0/54 |
| DiplopiaEye disorders | 1/51 | 0/54 |
| BronchiectasisRespiratory, thoracic and mediastinal disorders | 0/51 | 1/54 |
| DystoniaNervous system disorders | 0/51 | 1/54 |
| Esophageal varices hemorrhageGastrointestinal disorders | 0/51 | 1/54 |
| Event | Dexamethasone Sodium Phosphate | Placebo |
|---|---|---|
| PruritusSkin and subcutaneous tissue disorders | 14/51 | 2/54 |
| VomitingGastrointestinal disorders | 11/51 | 13/54 |
| PyrexiaGeneral disorders | 12/51 | 7/54 |
| NasopharyngitisInfections and infestations | 5/51 | 11/54 |
| CoughRespiratory, thoracic and mediastinal disorders | 5/51 | 9/54 |
| HeadacheNervous system disorders | 8/51 | 5/54 |
| FatigueGeneral disorders | 7/51 | 5/54 |
| Upper respiratory tract infectionInfections and infestations | 6/51 | 4/54 |
| NauseaGastrointestinal disorders | 0/51 | 6/54 |
| Blood culture positiveInvestigations | 4/51 | 6/54 |
The ITT population consisted of 105 participants, 51 of whom were assigned to the eDSP group and 54 in the placebo group. Efficacy endpoints were analyzed in the efficacy population, 6-9-year-olds (N=83), while the safety population included all 105 enrolled participants who received at least one dose of treatment.
| Age, Categorical(Participants) | Dexamethasone Sodium Phosphate | Placebo | Total |
|---|---|---|---|
| <=18 years | 51 | 54 | 105 |
| Between 18 and 65 years | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Dexamethasone Sodium Phosphate | Placebo | Total |
|---|---|---|---|
| Female | 24 | 26 | 50 |
| Male | 27 | 28 | 55 |
| Race (NIH/OMB)(Participants) | Dexamethasone Sodium Phosphate | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 4 | 2 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 4 | 2 | 6 |
| White | 41 | 47 | 88 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 3 | 5 |
| Region of Enrollment(Participants) | Dexamethasone Sodium Phosphate | Placebo | Total |
|---|---|---|---|
| United States | 13 | 15 | 28 |
| Denmark | 1 | 1 | 2 |
| Germany | 10 | 12 | 22 |
| Italy | 2 | 1 | 3 |
| Norway | 3 | 2 | 5 |
| Poland | 5 | 9 | 14 |
| Spain | 6 | 6 | 12 |
| Switzerland | 1 | 2 | 3 |
| United Kingdom | 10 | 6 | 16 |
| Rescored modified version of the International Cooperative Ataxia Rating Scale (RmICARS)(rmICARS Score) | Dexamethasone Sodium Phosphate | Placebo | Total |
|---|---|---|---|
| Mean | 9.8 ± 5.25 | 8.6 ± 5.66 | 9.2 ± 5.46 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2024 to primary completion in Dec 2025, 17 months.
Results were first posted in Apr 2026, 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexamethasone phosphate
Quince Therapeutics S.p.A.